Lupus Foundation of America1h
Investigator-initiated Study of CNTY-101, for People with Autoimmune Diseases, Including Systemic Lupus Erythematosus and Lupus Nephritis Announced
An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of ...
Lupus Foundation of America2d
New Study Identifies Predictors of Successful Glucocorticoid Discontinuation in Systemic Lupus Erythematosus Treatment
A new study found that low or absent disease activity, hydroxychloroquine (HCQ) use, and gradual reduction of GC dosing can ...
Lupus Foundation of America7d
Coping with the Mental Health Impacts of Lupus
Living with lupus can significantly affect your mental health. This January we are honoring Mental Wellness Month by exploring the intersection of lupus and mental health with a four-part series of ...
Lupus Foundation of America9d
UPDATE: Phase 1 Trial Begins for Investigational Therapy, CB-010, for Lupus Nephritis Treatment
The Phase 1 GALLOP study evaluating the investigational therapy, CB-010, for treatment of lupus nephritis has launched.
Lupus Foundation of America10d
Exagen Inc. Gains Approval for Advanced Lupus and Rheumatoid Arthritis Diagnostic Tests
Exagen Inc. has announced conditional approval from the New York State Department of Health for its innovative new biomarker ...
Lupus Foundation of America10d
New Study Suggests KLF2 May Play a Role in Neutrophil Regulation and the Development of Systemic Lupus Erythematosus
A new study investigates the role of Krüppel-like factor 2 (KLF2, a protein coding gene involved in a variety of regulatory ...